Literature DB >> 22538658

KSHV infection of B-cell lymphoma using a modified KSHV BAC36 and coculturing system.

Hyosun Cho1, Hyojeung Kang.   

Abstract

Kaposi's sarcoma-associated herpesvirus (KSHV) is the causative agent of two B cell lymphoproliferative diseases, namely primary effusion lymphoma (PEL) and multicentric Castleman's disease (MCD). KSHV infection of B cell lymphoma in vitro has been a long-standing battle in advancing human KSHV biology. In this study, a modified form of KSHV BAC36 named BAC36A significantly increased the fidelity of gene-targeted site-directed mutagenesis in the KSHV genome. This modification eliminates tedious screening steps required to obtain mutant clones when a KSHV BAC36 reverse genetic system is used. Coculturing B-cell lymphoma BJAB cells with KSHV BAC36A stably transfected 293T cells enabled us to infect BJAB cells with a KSHV virion derived from the KSHV BAC36A. The coculture system produced substantial amounts of KSHV infection to BJAB, meaning that KSHV virions were released from 293T cells and then infected neighboring BJAB cells. Owing to our success with the KSHV BAC36A and coculture system, we propose a new genetic system for the study of KSHV gene expression and regulation in B-cell lymphoma.

Entities:  

Mesh:

Year:  2012        PMID: 22538658     DOI: 10.1007/s12275-012-1495-9

Source DB:  PubMed          Journal:  J Microbiol        ISSN: 1225-8873            Impact factor:   3.422


  26 in total

1.  A complex translational program generates multiple novel proteins from the latently expressed kaposin (K12) locus of Kaposi's sarcoma-associated herpesvirus.

Authors:  R Sadler; L Wu; B Forghani; R Renne; W Zhong; B Herndier; D Ganem
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

2.  Role of the Kaposi's sarcoma-associated herpesvirus K15 SH3 binding site in inflammatory signaling and B-cell activation.

Authors:  Marcel Pietrek; Melanie M Brinkmann; Ilona Glowacka; Anette Enlund; Anika Hävemeier; Oliver Dittrich-Breiholz; Michael Kracht; Marc Lewitzky; Kalle Saksela; Stephan M Feller; Thomas F Schulz
Journal:  J Virol       Date:  2010-06-09       Impact factor: 5.103

Review 3.  Molecular biology of KSHV in relation to AIDS-associated oncogenesis.

Authors:  Whitney Greene; Kurt Kuhne; Fengchun Ye; Jiguo Chen; Fuchun Zhou; Xiufen Lei; Shou-Jiang Gao
Journal:  Cancer Treat Res       Date:  2007

4.  Productive lytic replication of a recombinant Kaposi's sarcoma-associated herpesvirus in efficient primary infection of primary human endothelial cells.

Authors:  Shou-Jiang Gao; Jian-Hong Deng; Fu-Chun Zhou
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

5.  Infection of primary human tonsillar lymphoid cells by KSHV reveals frequent but abortive infection of T cells.

Authors:  Jinjong Myoung; Don Ganem
Journal:  Virology       Date:  2011-02-25       Impact factor: 3.616

6.  Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8).

Authors:  J J Russo; R A Bohenzky; M C Chien; J Chen; M Yan; D Maddalena; J P Parry; D Peruzzi; I S Edelman; Y Chang; P S Moore
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-10       Impact factor: 11.205

7.  Efficient infection by a recombinant Kaposi's sarcoma-associated herpesvirus cloned in a bacterial artificial chromosome: application for genetic analysis.

Authors:  Fu-Chun Zhou; Yan-Jin Zhang; Jian-Hong Deng; Xin-Ping Wang; Hong-Yi Pan; Evelyn Hettler; Shou-Jiang Gao
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

8.  Genome-wide identification of binding sites for Kaposi's sarcoma-associated herpesvirus lytic switch protein, RTA.

Authors:  Jiguo Chen; Fengchun Ye; Jianping Xie; Kurt Kuhne; Shou-Jiang Gao
Journal:  Virology       Date:  2009-02-23       Impact factor: 3.616

9.  Kaposi's sarcoma-associated herpesvirus infection promotes invasion of primary human umbilical vein endothelial cells by inducing matrix metalloproteinases.

Authors:  Li-Wu Qian; Jianping Xie; Fengchun Ye; Shou-Jiang Gao
Journal:  J Virol       Date:  2007-04-18       Impact factor: 5.103

10.  Coordination of KSHV latent and lytic gene control by CTCF-cohesin mediated chromosome conformation.

Authors:  Hyojeung Kang; Andreas Wiedmer; Yan Yuan; Erle Robertson; Paul M Lieberman
Journal:  PLoS Pathog       Date:  2011-08-18       Impact factor: 6.823

View more
  6 in total

1.  Glycoprotein K8.1A of Kaposi's Sarcoma-Associated Herpesvirus Is a Critical B Cell Tropism Determinant Independent of Its Heparan Sulfate Binding Activity.

Authors:  Stephen J Dollery; Rey J Santiago-Crespo; Deboeeta Chatterjee; Edward A Berger
Journal:  J Virol       Date:  2019-03-05       Impact factor: 5.103

Review 2.  Recent advances in the study of Kaposi's sarcoma-associated herpesvirus replication and pathogenesis.

Authors:  Denis Avey; Brittany Brewers; Fanxiu Zhu
Journal:  Virol Sin       Date:  2015-04-23       Impact factor: 4.327

Review 3.  Primary lymphocyte infection models for KSHV and its putative tumorigenesis mechanisms in B cell lymphomas.

Authors:  Sangmin Kang; Jinjong Myoung
Journal:  J Microbiol       Date:  2017-04-29       Impact factor: 3.422

4.  Activation of the B cell antigen receptor triggers reactivation of latent Kaposi's sarcoma-associated herpesvirus in B cells.

Authors:  Semra Kati; Edward H Tsao; Thomas Günther; Magdalena Weidner-Glunde; Thomas Rothämel; Adam Grundhoff; Paul Kellam; Thomas F Schulz
Journal:  J Virol       Date:  2013-05-15       Impact factor: 5.103

5.  Cordycepin is a novel chemical suppressor of Epstein-Barr virus replication.

Authors:  Eunhyun Ryu; Myoungki Son; Minjung Lee; Kanghyo Lee; Jae Youl Cho; Sungchan Cho; Suk Kyeong Lee; You Mie Lee; Hyosun Cho; Gi-Ho Sung; Hyojeung Kang
Journal:  Oncoscience       Date:  2014-12-18

6.  A KSHV microRNA enhances viral latency and induces angiogenesis by targeting GRK2 to activate the CXCR2/AKT pathway.

Authors:  Wan Li; Xuemei Jia; Chenyou Shen; Mi Zhang; Jingyun Xu; Yuancui Shang; Kaixiang Zhu; Minmin Hu; Qin Yan; Di Qin; Myung-Shin Lee; Jianzhong Zhu; Hongmei Lu; Brian J Krueger; Rolf Renne; Shou-Jiang Gao; Chun Lu
Journal:  Oncotarget       Date:  2016-05-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.